安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- Home | Biogen
Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities We apply deep understanding of human biology and leverage different modalities to advance first-in-class treatments or therapies that deliver superior outcomes
- Company | Biogen
Founded in 1978, Biogen is a leading biotechnology company that pioneers innovative science to deliver new medicines to transform patients’ lives and to create value for shareholders and our communities
- Careers | Biogen
Everyone at Biogen contributes to our mission to create transformative medicines for people who need them the most Explore our business areas to discover where you can make an impact on our team
- Leadership | Biogen
Meet our executive leadership team Inspired by the science: Mother, daughter reflect on 50 plus years at Biogen
- Biogen Receives U. S. FDA Breakthrough Therapy Designation for . . .
CAMBRIDGE, Mass , Oct 09, 2024 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) – Biogen announced today that felzartamab, an investigational anti-CD38 monoclonal antibody, has received Breakthrough Therapy Designation (BTD) from the U S Food and Drug Administration (FDA) for the treatment of late antibody-mediated rejection (AMR) without T
- Página inicial | Biogen
A Biogen é uma empresa líder global em biotecnologia que é pioneira em ciência com foco em inovações para doenças complexas e devastadoras
- Biogen and City Therapeutics Announce Strategic Research Collaboration . . .
CAMBRIDGE, Mass , May 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc (Nasdaq: BIIB) and City Therapeutics, Inc , a privately held biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced a strategic collaboration to develop select novel RNAi therapies
- Biogen and Stoke Therapeutics Enter into Collaboration to Develop and . . .
Biogen receives exclusive rights to commercialize zorevunersen in the rest of the world Upon closing of this transaction, Stoke will receive an upfront payment of $165 million The parties will share external clinical development costs for zorevunersen (30 percent Biogen; 70 percent Stoke)
|
|
|